by Lauren Baggett, University of Georgia Credit: CC0 Public DomainLast summer, the U.S. Food and Drug Administration fully approved the first drug shown to slow the progress of Alzheimer’s. But new research from the University of Georgia suggests that patients and caregivers may not experience any benefit from the drug in their daily lives. The drug,...
Nancy A. Melville PHOENIX — Early responders to zilucoplan, the newly approved medication for myasthenia gravis (MG), have sustained benefit for up to 60 weeks, new analyses show. “The information [in the studies] is valuable in making clinical decisions in managing MG, which is a chronic autoimmune condition that requires long-term use of immunosuppressives,” Xinli...
UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER HOUSTON ― A blood test, combined with a risk model based on an individual’s history, more accurately determines who is likely to benefit from lung cancer screening than the current U.S. recommendation, according to a study published today in the Journal of Clinical Oncology led by researchers...
